Caladrius Biosciences has acquired an exclusive worldwide license to data from Shire’s late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.
Research into synthetic biology from the Universities of Warwick and Surrey has revealed that bacteria could be programmed to produce drugs.
Mylan said that it will launch two new HIV treatments, Symfi Lo and Cimduo, which have been approved in February this year by the US Food and Drug Administration (FDA).
LEO Pharma has sold product portfolio of 10 products to Swedish company Karo Pharma for €260m.
MedImmune, the global biologics research and development arm of AstraZeneca, is creating a stand-alone company for early-stage inflammation and autoimmunity biologics.
Senti Biosciences has completed a $53m round of funding to support the expansion of their therapeutic design platform.
BenevolentAI has acquired an advanced drug discovery and development facility on the Babraham Research Campus in Cambridge, UK, for an undisclosed sum.
A new collaborative project has been launched to develop a Zika virus vaccine that is suitable for use in pregnancy.
Gilead Sciences’ subsidiary Kite has agreed to use Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology platform to develop cancer treatments in a collaboration deal worth over $3bn.
Scientists from Emulate and Roche have partnered to use Organ-Chips for testing of efficacy and safety of new antibody therapeutics and combination therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.